References
- Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev. Vaccines 12(10), 1155–1172.
- Saccheri F, Pozzi C, Avogadri F et al. Bacteria-induced gap junctions in tumors favour antigen cross-presentation and antitumor immunity. Sci. Transl. Med. 2, 44ra57 (2010).
- Vacchelli E, Senovilla L, Eggermont A et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2(3), e23510 (2013).
- Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunther. 54, 187–207 (2005).
- Chauchet X, Wang Y, Polack B, Toussaint B, Le Gouellec A. Live attenuated bacteria as a cancer vaccine vector. Expert Rev. Vaccines 12(10), xxxx–xxxx.
- Bracci L, Capone I, Moschella F, Proietti E Belardelli F. Exploiting dendritic cells in the development of cancer vaccines. Expert Rev. Vaccines 12(10), 1195–1210.
- Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex-vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790–802 (2007).
- Fridman WH, Pagès F, Sautés-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
- Ungaro F, Conte C, Quaglia F, Tornesello ML, Buonaguro FM, Buonaguro L. VLPs and particle strategies for cancer vaccines. Expert Rev. Vaccines 12(10), 1173–1193.
- Parmiani G, DiFilippo A, Novellino L, Castelli C. Unique tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178, 1975–1979 (2007).
- Rammensee HG, Singh-Jasuja H. HLA-ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev. Vaccines 12(10), 1211–1217.
- Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091(2012).
- Haen SP, Rammensee H-G. The repertoire of human tumor-associated epitopes identification and selection of antigens and their application in clinical trials. Curr. Opin. Immunol. 25, 277–283 (2013).
- Aurisicchio L, Mancini R, Ciliberto G. Cancer vaccination by electro-gene-transfer. Expert Rev. Vaccines 12(10), 1127–1137.
- Impellizeri JA, Ciliberto G, Aurisicchio L. Electro-gene-transfer as a new tool for cancer immunotherapy in animals. Vet. Comp. Oncol. doi:10.1111/vco.12006 (2012) (Epub ahead of print).
- Senovilla L, Vacchetti E, Garcia P et al. Trial watch. DNA vaccines for cancer therapy. Oncoimmunology 2, 4 e23803 (2013).
- Berzofsky JA, Wood LV, Terabe M. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Rev. Vaccines 12(10), 1115–1118.
- Eggermont A, Robert C. New drugs in melanoma: It’s a whole new world. Eur. J. Cancer 47, 2150–2157 (2011).
- Topalian SL, Sznol M, Brahmer JR et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J. Clin. Oncol. 31(Suppl.), Abstract 3002 (2013).
- Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J. Med. 363, 411–422 (2010).
- Schwartzentruber D, Lawson DH, Richards JM et al. Gp100 peptide vaccine andd interleukin-2 in patients with advanced melanoma. N. Engl J. Med. 364, 2119–2127 (2011).
- Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induced market T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18,1386–1394 (2011).